For research use only; not for diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).
The LANCE® Ultra Human Oncostatin M Detection Kit is designed for detection and quantitation of human oncostatin M (OSM) in buffered solution and cell culture media using a homogeneous TR-FRET (no-wash steps, no separation steps) assay.
LANCE® and LANCE® (Lanthanide chelate excite) Ultra are our TR-FRET (time-resolved fluorescence resonance energy transfer), homogeneous (no wash) technologies. One antibody of interest is labeled with a donor fluorophore (a LANCE Europium chelate) and the second molecule is labeled with an acceptor fluorophore (ULight™ dye). Upon excitation at 320 or 340 nm, energy can be transferred from the donor Europium chelate to the acceptor fluorophore if sufficiently close for FRET (~10 nm). This results in the emission of light at 665 nm.
Oncostatin M, also known as OSM, is a growth factor encoded by the OSM gene in humans. OSM is a pleiotropic cytokine that belongs to the interleukin 6 group of cytokines and most closely resembles leukemia inhibitory factor (LIF) in both structure and function. The fully active 196 residue OSM is the predominant form isolated from activated monocytes and T lymphocytes, and corresponds to a glycoprotein of 28 Kda. It plays a key role in liver development, hematopoiesis, inflammation and possibly CNS development and is associated with bone formation and resorption. OSM regulates cytokine production, including IL-6, G-CSF and GM-CSF from endothelial cells and can both inhibit and stimulate cell proliferation. OSM signals through cell surface receptors that contain the protein gp130.
Assay Target | Oncostatin M |
---|---|
Assay Target Class | Protein |
Automation Compatible | Yes |
Detection Method | Time-Resolved Fluorescence (TRF), TR-FRET |
Experimental Type | In vitro |
Product Brand Name | LANCE Ultra |
Shipping Condition | Blue Ice |
Unit Size | 500 Assay Points |
The introduction of enzyme-linked immunosorbent assays (ELISAs) in the early 1970’s offered researchers a non-radiometric immunoassay platform without compromising sensitivity. Over the last 50 years scientists have made huge strides in disease research and drug discovery and a demand for greater assay throughput and sensitivity has evolved. In response, more robust immunoassays have been developed to address some of the limitations of the standard, colorimetric ELISA.
Find out about the most common limitations of traditional ELISAs and how different ELISA alternative technologies address these limitations.